Description
The skeptic identified this as a weak assumption underlying biomarker-guided approaches, yet it’s fundamental to patient selection strategies. Current evidence is correlative rather than mechanistically validated.
Source: Debate session sess_SDA-2026-04-01-gap-001 (Analysis: SDA-2026-04-01-gap-001)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:54.780860+00:00”, “resolution_summary”: “Resolved by hypothesis h-25ec762b3f: CSF YKL-40 as a Priming-Specific Chitinase Marker. Supporting evidence includes debate sess_SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e_20260416-135601.”, “match_counts”: {“hypothesis_matches”: 3, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-25ec762b3f”, “title”: “CSF YKL-40 as a Priming-Specific Chitinase Marker”, “score”: 0.231, “reason”: “13 token overlaps; entity overlap: csf”, “analysis_id”: “SDA-2026-04-06-gap-debate-20260406-062039-3b945972”, “target_gene”: “CHI3L1/YKL-40”, “target_pathway”: null, “disease”: “biomarkers”, “composite_score”: 0.714477, “confidence_score”: 0.72, “status”: “proposed”, “pubmed_evidence_ids”: [“29618783”, “33328329”, “33788986”, “37756391”, “38733586”]}, {“id”: “h-dffb42d9de”, “title”: “Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin”, “score”: 0.23, “reason”: “13 token overlaps; entity overlap: csf”, “analysis_id”: “SDA-2026-04-06-gap-debate-20260406-062039-3b945972”, “target_gene”: “CHI3L1/TREM2/NRGN”, “target_pathway”: null, “disease”: “biomarkers”, “composite_score”: 0.756553, “confidence_score”: 0.68, “status”: “proposed”, “pubmed_evidence_ids”: [“29198979”, “30814620”, “32084334”, “32783918”, “33516818”]}, {“id”: “h-7d24e096”, “title”: “CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification”, “score”: 0.226, “reason”: “18 token overlaps; entity overlap: csf”, “analysis_id”: “SDA-2026-04-26-trem2-showcase”, “target_gene”: “sTREM2/membrane-TREM2/ADAM10”, “target_pathway”: null, “disease”: “neuroimmunology”, “composite_score”: 0.801, “confidence_score”: 0.8, “status”: “promoted”, “pubmed_evidence_ids”: [“34661615”, “38760857”, “39444037”, “40593718”, “41198899”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e_20260416-135601”, “title”: “The skeptic raised evidence that APOE4 carriers show enhanced cholesterol synthesis, suggesting the lipid binding deficit may be compensatory rather than harmful. This fundamental mechanistic question affects all lipid-based therapeutic approaches.\n\nSource: Debate session sess_SDA-2026-04-01-gap-auto-fd6b1635d9 (Analysis: SDA-2026-04-01-gap-auto-fd6b1635d9)”, “score”: 0.428, “reason”: “10 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112812-429571d2”, “title”: “The theorist proposed this novel approach to enable safe agonism across disease stages, but no evidence exists for such selective pathway activation. This represents a critical gap for developing safer TREM2 therapeutics.\n\nSource: Debate session sess_SDA-2026-04-01-gap-001 (Analysis: SDA-2026-04-01-gap-001)”, “score”: 0.37, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112812-429571d2”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1”, “title”: “The debate revealed conflicting evidence about C1q’s role - some studies show it drives synaptic loss while others suggest it facilitates protective amyloid clearance. This fundamental mechanistic uncertainty undermines therapeutic targeting strategies.\n\nSource: Debate session sess_SDA-2026-04-01-gap-v2-691b42f1 (Analysis: SDA-2026-04-01-gap-v2-691b42f1)”, “score”: 0.347, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1”, “quality_score”: 0.58, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112945-6a9ce0a3”, “title”: “The debate revealed that DNAJB6 evidence is limited to polyglutamine aggregation, with no direct testing of heterologous cross-seeding inhibition. This fundamental gap undermines the universal inhibitor hypothesis and requires specific cross-seeding assays.\n\nSource: Debate session sess_SDA-2026-04-01-gap-9137255b (Analysis: SDA-2026-04-01-gap-9137255b)”, “score”: 0.33, “reason”: “6 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112945-6a9ce0a3”, “quality_score”: 0.79, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-113038-57244485_20260412-215703”, “title”: “The debate revealed conflicting evidence about whether connexin-43 mediates mitochondrial transfer through gap junctions or tunneling nanotubes. This mechanistic uncertainty undermines therapeutic targeting strategies and requires direct experimental disambiguation.\n\nSource: Debate session sess_SDA-2026-04-01-gap-20260401231108 (Analysis: SDA-2026-04-01-gap-20260401231108)”, “score”: 0.318, “reason”: “6 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-113038-57244485”, “quality_score”: 0.74, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}